Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
PARDES BIOSCIENCES, INC. Create: Alert

All | News | Filings
Date FiledTypeDescription
07/17/2023 8-K Quarterly results
05/18/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Re: Separation Agreement and General Release of Claims",
"Appointment of Consultant; Services. As of the Effective Date, Company appoints Consultant and Consultant hereby accepts appointment as consultant to the Company. In this capacity, Consultant shall perform the services set forth on Exhibit 1 . Consultant and Company shall work together to delineate the scope of each project and the timeline and deliverables related thereto. Consultant is expected to work no more than 12 hours per month for the Company through July 31, 2023, and then no more than 6 hours per month thereafter, which the parties acknowledge is less than 20% of Consultant’s average weekly service level with the Company over the 36 months prior to the end of the Term. 2. Term; Termination. Upon the Separation Agreement becoming effective, this Consulting Agreement will be effec..."
05/05/2023 8-K Quarterly results
04/21/2023 8-K Quarterly results
04/03/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Ot...
Docs: "Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19 Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy, vaccinated adults without risk factors for progression to severe disease experienced rapid clearance of SARS-CoV-2 virus and evidence of rapid alleviation of targeted and key COVID-19 symptoms independent of treatment arm Based on these results, Pardes to suspend further clinical development of pomotrelvir and explore a range of strategic alternatives CARLSBAD, Calif. April 03, 2023 – Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing a n..."
11/07/2022 8-K Quarterly results
Docs: "Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023 CARLSBAD, Calif. November 7, 2022 – Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of COVID-19 in adult and pediatric patients, today reported financial results for the third quarter ended September 30, 2022 and provided a business update. “We made significant progress in our pursuit to bring a stand-alone, easily administered oral treatment to patients suffering from COVID-19, highlighted by the commencement of our PBI-0451 Phase 2 trial in September 2022..."
10/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors CARLSBAD, Calif. September 14, 2022 – Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, today announced the appointments of Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to its Board of Directors. “As we advance PBI-0451 into a Phase 2 study, I am delighted to welcome both Laurie and John to our Board and look forward to leveraging their deep experience and insights as we take the next steps in development,” said Tom Wiggans, Chief Executive Officer and Chair of the Board of ..."
09/13/2022 8-K Other Events  Interactive Data
08/15/2022 8-K Quarterly results
Docs: "Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update CARLSBAD, Calif. August 15, 2022 – Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. “The second quarter was highlighted by the completion of several additional components of our full Phase I and non-clinical programs, a Fast Track designation, and collaborative engagement with the FDA around our PBI-0451 clinical development program. As a result of those regulatory interactions, we are pleased to confirm we will be ..."
06/10/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/29/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Year Ended December 31, Period from February 27, 2020 through December 31, 2021 2020 Operating expenses: Research and development $ 28,152 $ 4,563 General and administrative 10,336 750 Total operating expenses 38,488 5,313 Loss from operations 38,488 5,313 Other income : Interest expense, net — Change in fair value of SAFE liability — Total other expense, net Net loss and comprehensive loss $ $ Weighted-average number of common shares —basic and diluted 3,800,506 — Net loss per share — basic and diluted $ $ — Pardes Biosciences, Inc. Condensed Consolidated Balance Sheets December 31, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 268,678 $ 3,410 Prepaid expenses and other current assets 6,581 194 Total current assets 275,259 3,604 Total assets $ 275,259 $ 3,604..."
03/24/2022 8-K Investor presentation
Docs: "V-2 SARS MERS 229E NL63 OC43"
03/09/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
02/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "V-2 SARS MERS 229E NL63 OC43",
"2 100, 300, 1050, 2100"
01/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "2 229E OC43 SARS NL63 MERS HKU P3"
12/30/2021 8-K Quarterly results
12/27/2021 8-K Quarterly results
12/23/2021 8-K Quarterly results
12/23/2021 8-K Quarterly results
12/21/2021 8-K Quarterly results
12/01/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021"
11/23/2021 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
11/18/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Presentation"
11/09/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Merger Agreement"
06/29/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/19/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy